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INTRODUCTION
Anaesthesia for intracranial surgery.
If  good anaesthesia is to be provided to the patient undergoing surgery for an 
expanding  intracranial  lesion,  certain  principles  should  be  borne  in  mind.  These  principles 
include:
1. Careful preoperative assessment of the patient.
2. Awareness of abnormal intracranial dynamics in the presence of an intracranial mass lesion
3. The importance of a smooth induction of anesthesia 
4.  Adequate  depth  of  anesthesia  and  complete  muscle  paralysis  before  laryngoscopy  and 
intubation 
5. The choice of a maintenance technique that does not increase ICP and allows adequate CPP. 
Failure to adhere to these principles may lead to sudden increases in intracranial 
pressure,  decreased  cerebral  perfusion  pressure,  and  regional  ischemia.  In  the  closed  skull, 
internal herniation of brain tissue through the tentorial notch or the foramen magnum may occur. 
External brain herniation, with increased bleeding and rupture of cerebral cortex, may occur after 
the  dura  mater  has  been  opened  if  these  anesthetic  parameters  are  not  controlled. 
Neuroanesthesia, therefore, plays an important role in the reduction of morbidity and mortality in 
the surgery of intracranial lesions of all types, including neoplasm’s - not only in the operating 
room, but also in the pre- and postoperative care of the neurosurgical patient.
AIM
The aim of the study is to evaluate the efficacy of oral clonidine 
as  a  premedicant  in  providing  intra-operative  haemodynamic 
stability in neurosurgical patients undergoing craniotomies.

REVIEW  OF  LITERATURE
Cerebral circulation
The brain, though representing 2% of the total body weight, it receives one fifth of 
the resting cardiac output. This blood supply is carried by the two internal carotid arteries (ICA) 
and the two vertebral arteries that anastomose at the base of the brain to form the circle of Willis. 
Carotid arteries and their branches (referred to as the anterior circulation) supply 
the  anterior  portion  of  the  brain  while  the  vertebro-basilar  system (referred  to  as  posterior 
circulation) supplies the posterior portion of the brain.
Regulation of cerebral blood flow
Cerebral blood flow (CBF) in man is about 50 ml / 100 g of brain / minute. It has 
been shown that CBF, cerebral blood volume (CBV) and cerebral energy metabolism measured 
as cerebral  metabolic  rate of oxygen (CMRO2)  or of glucose (CMRglu)  are all  coupled and 
higher in gray than white matter. This means that the oxygen extraction fraction (OEF) remains 
about the same (approximately forty per cent) throughout the brain, therefore, in normal resting 
human brain, CBF (i.e. flow) is a reliable reflection of CMRO2 (i.e. function) (Leenders et al., 
1990). 
CBF depends on cerebral perfusion pressure (CPP) and cerebrovascular 
resistance. The perfusion pressure is the difference between systemic arterial pressure and 
venous pressure at exit of the subarachnoid space, the latter being approximated by the 
intracranial pressure.
Autoregulation
It  is  a  characteristic  of  the  brain  to  adjust  its  own  blood  supply.  In  normal 
individuals,  CBF remains  constant  when the  mean  arterial  pressure  is  between  60  and 160 
mmHg, which, in normal circumstances, when the intracranial venous pressure is negligible, is 
the same as the CPP (Powers 1991). Whether myogenic, metabolic or neurogenic processes are 
responsible  for  this  process  is  unknown (Aaslid  et  al.,  1989).  Autoregulation  is  impaired or 
abolished in damaged areas of the brain (e.g. by ischemia, trauma, etc.) so that CBF becomes 
pressure passive and follows perfusion pressure (Strandgaard and Paulson 1984 and Deardin 
1985).  

INTRACRANIAL PRESSURE
 
Once  the  fontanelles  are  closed  the  skull  is  a  rigid  box,  which  can  only 
accommodate a limited volume. At an early age some separation of the sutures may occur.
The  normal  structures  within  the  skull  have  more  or  less  stable  volume.  There  are  some 
variations in volume depending on the person’s activities, cardiovascular as well as pulmonary 
status.  These variations  are  temporary and the intracranial  pressure goes  back quickly to  its 
normal level.
 
The skull is not a completely closed sphere; there are several openings mainly in 
the base of the skull. It is believed that intracranial pressure is a reflection of the atmospheric 
pressure, which is conducted through the large neck vessels.
NORMAL INTRACRANIAL PRESSURE
The normal pressure for is 15 mmHg or 150 mm - 200 mm of water. Accurate 
measurement of pressure in newborn and infants is difficult to obtain but it is believed that in the 
first  few months of life the intracranial  pressure is lower.  Values up to 8 mmHg have been 
considered to be normal in the first few months of life.
The intracranial pressure is closely related to brain perfusion. The cerebral blood 
flow is  dependent  on  the  intracranial  pressure.  In  a  simplified  statement  cerebral  perfusion 
pressure is the difference between the systemic blood pressure and the intracranial pressure. For 
this  reason  the  intracranial  pressure  needs  to  be  maintained  at  a  steady  state.  This  is 
accomplished by dynamic equilibrium of intracranial components. 
As the skull is a rigid box any extra volume added to the intracranial cavity needs 
to  be at  the expense of normal intracranial  components  in order to maintain the intracranial 
pressure at a normal level.
In the early stages adjustment is made to maintain an ICP within normal range. 
This is called autoregulation. If the process continues the increase in volume will be associated 
with gradual rise in ICP. This continues up to an ICP of about 50mm Hg when the pattern 
changes and the intracranial cavity loses its compliance and behaves as a solid box .As seen 
above there will be steep rise in the curve and incremental rise of the intracranial pressure.
DYNAMICS OF RAISED INTRACRANIAL PRESSURE
Raised intracranial pressure could be the result of the following:
1. Increase of the volume of the normal content of the intracranial cavity,  as increase in the 
volume of CSF as in hydrocephalus, increase in the volume of the brain tissue itself as in brain 
oedema or increased cerebral blood volume.
2. Extra volume added to the intracranial cavity as in tumors or haematomas.
Where an extra volume is added to the intracranial cavity this has to be at the expense of the 
normal contents. To start with the cerebrospinal fluid is squeezed out, we find that the ventricles 
become compressed and displaced. There will be paucity of subarachnoid spaces and the basal 
cisterns become less discernible. Once a state is reached where no more CSF could be expulsed, 
a change in the cerebral blood flow occurs. As mentioned cerebral blood perfusion is related to 
intracranial pressure. With the rise of intracranial pressure there is diminished cerebral blood 
flow and more space is provided for the extra volume. However a state would be reached where 
any further decrease in cerebral blood flow would lead to cerebral ischaemia. In this situation the 
brain itself starts to herniate through the hiatus of the tentorium and foramen magnum. At this 
stage the patient’s  condition is  precarious  and needs urgent  action to  reduce the intracranial 
pressure.
Increase blood volume can occur as a result  of a blockage to venous drainage 
from the cranial cavity or due to vasodilatation. It is very important to appreciate that cerebral 
blood vessels are very sensitive to changes in blood gases especially carbon dioxide. High PCO2 
results in vasodilatation and increase in cerebral blood volume.
The average brain weight varies from 1000 to 1500 grams.
MANAGEMENT OF RAISED INTRACRANIAL PRESSURE
 
The first step is to find the cause of the raised intracranial pressure and remove it 
if possible. If there is excessive cerebrospinal fluid as in hydrocephalus then shunt procedure or 
external drainage should be instituted. If there is a resectable tumor then this should be removed. 
In cases where there are  no surgically treatable  cause efforts  should be directed at  reducing 
intracranial pressure by one of the following means:
 
Osmotic  Diuretic:  This  acts  by dehydrating  the  brain.  This  is  achieved by removing extra 
cellular fluid by creating an osmotic gradient across the capillary wall. The most commonly used 
agent is Mannitol. This is a carbohydrate, which is not metabolised in the blood and remains 
entirely in the extracellular space. The dose is 0.25- 1 gram per kilogram body weight over 10 - 
15 minutes. 20% of the solution is used. The effect of Mannitol lasts about 4 to 6 hours.
Mannitol has some side effects; its action is reduced with repeated doses and can cause systemic 
acidosis and renal failure due to increase plasma osmolarity. After Mannitol is stopped there is 
rebound of intracranial pressure.
Other diuretics used are Furosemide, which is a renal diuretic. 
Diuretics  could be used as a  temporary measure while  the patient  is  prepared for definitive 
surgical treatment.
STEROIDS
These are mainly used to reduce brain swelling around brain tumors. They are 
very effective in these conditions.
CSF DRAINAGE
This is an effective and rapid way of reducing intracranial pressure in cases where 
ventricles are visible and can be cannulated. However in severe brain oedema with collapsed 
ventricles it is difficult to get into the ventricle. The ventricular catheter could be used to monitor 
intracranial pressure at the same time.
HYPERVENTILATION 
As mentioned before  cerebral  blood vessels  are  sensitive  to  changes  in  blood 
gases. The aim of hyperventilation is to reduce the PCO2 to a level around 30 mmHg. Low PCO2 
will  cause  vasoconstriction  and reduced intracranial  blood volume.  Levels  below 30 mmHg 
should be avoided as it can cause cerebral ischaemia.
BARBITURATE
Barbiturate is used to induce deep coma, where there is a reduction in metabolic 
rate, oxygen consumption and CO2 production. This method is used only when all other means of 
treatment failed.
Anesthesia for craniotomy 
It is not surprising that anesthesia for craniotomy presents special 
considerations.  The  brain  is  enclosed  in  a  rigid  skull and the  majority  of 
craniotomies are performed for the treatment of space occupying lesions. At 
the same time, the brain is a highly vascular organ presenting potential for 
massive peri-operative hemorrhage. Tolerance of the brain to interruption of 
substrate delivery is minimal. 
Anesthetics  and  physiologic  factors  controlled  by  the 
anesthesiologist have  profound  effects  on  the  brain.  Interactions  between 
anesthesia and surgical outcome can be expected. 
Preoperative evaluation 
The initial approach to the patient requiring craniotomy is similar 
to that of all other patients. There are several additional considerations. It is 
important  to  obtain  an  appropriate  baseline neurological  evaluation.  At 
emergence from anesthesia, failure to recover baseline neurological function 
can be attributed to surgery, anesthesia, or an interaction between the two. It 
is incumbent on the anesthesiologist to recognize changes from baseline so as 
to participate in making the diagnosis. It is also important to gain insight into 
the  magnitude  of  intracranial hypertension  and  possible  interactions  with 
anesthetic agents. Acute changes in intracranial pressure (ICP; e.g., epidural 
hematoma)  are  potentially  more  devastating  and  are  likely  to be  more 
sensitive  to  anesthetic  effects.  The  anesthesiologist also  can  benefit  from 
appreciating  the  characteristics  of  the lesion  with  respect  to  potential  for 
major hemorrhage. 
 
Monitoring 
For most craniotomies, monitoring consists of standard monitors 
in addition to an intra-arterial  catheter.  The arterial  catheter is  valuable in 
providing strict  control  of  blood pressure  (particularly during emergence). 
Central  venous  pressure  (CVP)  monitoring is  usually  not  required  for 
management of tumors unless the case is expected to be exceedingly long or 
if  major  hemorrhage is  expected  (e.g.,  vascular  meningioma,  tumor 
encasement of major vessels). Otherwise, indications for CVP and pulmonary 
artery pressure monitoring remain the same as for other patient populations 
dictated principally by cardiac, renal, and pulmonary status. 
    Use  of mannitol  essentially  voids  urine  output  as  a  monitor  of 
intravascular volume status. The brain receives approximately 20% of cardiac 
output when the body is at rest. If cardiac output is approximately 5 L•min-1, 
it  is  easy  to  appreciate  that  uncontrolled  hemorrhage can  result  in  rapid 
exsanguination. The CVP monitor will aid resuscitation. An important reason 
for  placement  of  a  central venous  catheter  is  delivery  of  vasoactive 
medications.  It  is sometimes  difficult  to  predict  whether  the  surgeon will 
request blood  pressure  to  be  increased  (e.g.,  during  temporary  vascular 
occlusion of  the  parent  vessel)  or  decreased (e.g.,  to  facilitate clipping or 
reduce rate  of  hemorrhage).  Delivery  of  drugs  into the  central  circulation 
provides the fastest possible onset of action and shortens the feedback loop 
for dose titration facilitating exquisite control of blood pressure within the 
desired range. 
Routine use of intra-operative electrophysiological monitoring to 
detect  ischemia  remains  controversial.  Although  monitoring of  evoked 
potentials makes sense, there are numerous reports of false positive and false 
negative  readings.  Some  advocate use  of  electroencephalographic  (EEG) 
monitoring for the purposes of pharmacologically inducing burst suppression 
for  neuroprotection. Efficacy  is  unsupported  by  experimental  literature 
although the risk seems small. Monitoring of cranial nerve function is often 
employed  during  posterior  fossa  procedures.  Implications for  anesthesia 
largely pertain to limitation in use of muscle relaxants. Although there is no 
contraindication to  use  of  relaxants during induction and positioning,  it  is 
important  to  assure recovery  of  neuromuscular  function  prior  to  surgical 
stimulation of the cranial nerves located in the vicinity of the lesion. 
Transcranial  Doppler  (TCD)  monitoring  may  be  of  value 
preoperatively in  screening  for  vasospasm.  Intra-operative  use  during 
craniotomy is  cumbersome and unsubstantiated as  a  modifier  of  outcome. 
There is increasing hope that computerized analysis of TCD waveforms may 
provide useful data on intracranial pressure (ICP) and this could be useful 
during induction.  Clearly  TCD can identify  complete obstruction to  blood 
flow.  More  useful  information  regarding magnitude  of  ICP  allowing 
calculation of cerebral perfusion pressure is not currently available. 
Premedication
The goals of premedication in craniotomies are to avoid anxiety, 
provide sedation without causing respiratory depression which would cause 
an  increase  in  PaCO2  which  would  cause  an  increase  in  cerebral  blood 
volume and thereby increasing ICP. In such a setting           α2 – agonists such 
as clonidine serve as a useful choice.
Anaesthesia induction 
Concerns unique to induction of anesthesia  for  craniotomy are 
principally  related  to  ICP  in  the  case  of  mass  lesions  or  prevention of 
hemorrhage  in  the  case  of  vascular  lesions.  The  history  of effects  of 
anesthetics  on ICP during induction began in the 1960s when the earliest 
measurements were made on patients anesthetized for tumor surgery. Major 
increases in ICP were observed with anesthetic induction. In the subsequent 
zeal to provide optimal care, it was felt that any increase in ICP could only be 
adverse to the patient and thus use of anesthetics known to increase ICP was 
discouraged. Although logical, this came at some cost. Something must be 
used  to  provide  anesthesia  and  those  drugs known  to  reduce  ICP  (e.g., 
thiopental)  typically  have  prolonged durations  of  action  or  produce 
hemodynamic  instability.  In  fact, data  relevant  to  effects  of  various 
anesthetics on ICP in humans is limited. Most information has been derived 
from  animal  studies. More  important,  there  is  little  data  regarding  any 
relationship between anesthetic effects on ICP and outcome from craniotomy.
Case  reports in  the  literature  showing  a  causal  relationship 
between  anesthetics and  brain  herniation  on  induction  are  almost  non-
existent.  The one  exception  to  this  is  patients  with  an  occult  lesion 
undergoing surgery for non-neurosurgical  procedures.  The vast  majority of 
patients  anesthetized  for  craniotomy  emerge  from  anesthesia either  with 
neurological status unchanged or with changes directly attributable to the site 
of surgery. As a result, it is difficult to advocate any specific anesthetic or 
technique  for  the  purpose of  induction.  We  do  know that  ICP  effects  of 
volatile  anesthetics can  be  blunted  by  simultaneous  moderate 
hyperventilation.  We also  know  that  high  concentrations  of  volatile 
anesthetics  perturb cerebral  autoregulation.  We  also  know  that  there  are 
numerous methods  to  blunt  hemodynamic  responses  to  endotracheal 
intubation and  application  of  the  pin  head-holder.  Cumulatively  these 
concerns must be weighed when inducing anesthesia for craniotomy. 
With respect to cerebral aneurysms, ICP is of less concern than is 
prevention of abrupt and major increases in mean arterial pressure (MAP) that 
may  contribute  to  rupture  of  the  lesion. In  this  case,  there  is  abundant 
evidence  that  a  poorly  controlled hemodynamic  state  during  induction  is 
contributory. The mortality rate associated with aneurysmal rupture during 
induction is substantial. The goal is avoidance of hypertension. If an error is 
to  be  made  it  should  be  towards  hypotension.  Some  advocate purposeful 
reduction  of  MAP  during  induction  with  vasodilatory agents  (e.g., 
nitroprusside) to insure against hypertensive responses to intubation. This is 
usually unnecessary. Instead, controlled and progressive increases in depth of 
anesthesia sufficient to blunt responses to intubation are sufficient to prevent 
hemorrhage. This is an induction procedure that should not be rushed. 
Anaesthesia maintenance 
Maintenance  of  anesthesia  during  craniotomy  is  usually 
uncomplicated and  generic  in  many  respects.  There  are  two  special 
considerations, however. In patients with intracranial mass lesions, brain bulk 
can be a problem, particularly when the dura is being opened. A swollen brain 
can herniate through the dural defect prohibiting further dural incision. In this 
circumstance the anesthesiologist is frequently requested to "relax" the brain. 
There are multiple methods by which this can be achieved. Usually several 
changes are  made  simultaneously  which  cumulatively  result  in  improved 
operating  conditions.  The  anesthesiologist  can  often  prevent this  problem 
during patient positioning by assuring the head is sufficiently elevated above 
the heart to promote venous drainage. Further head elevation intraoperatively 
can  often  cause  dramatic reduction  in  brain  bulk.  This  must  be  weighed 
against  the  risk of  air  embolism  in  which  case  transcardiac  Doppler 
monitoring might be considered.   Placement of the head 10–15 above the 
heart  is  usually  sufficient to  promote  venous  drainage  without  risk  of  air 
embolism or hemodynamic instability. 
Reduction in brain bulk can also be achieved by discontinuation 
of  inhalation  anesthetics  that  are  known  vasodilators.  The  first drug  to 
discontinue is nitrous oxide. It is rapidly eliminated and a greater vasodilator 
than isoflurane because nitrous oxide does not have compensatory reduction 
in metabolic rate causing coupled reduction in cerebral  blood flow (CBF). 
Temporary discontinuation of the volatile anesthetic may also be of benefit. 
There is no evidence that opioids increase brain bulk.  There is 
evidence  that  opioids  increase  ICP.  This  effect,  however, is  modest  and 
transient.  Human  study  has  provided  convincing evidence  that  opioids 
increase ICP as a result of effects on MAP. When autoregulation is intact, 
reduced MAP causes  vasodilatation and a  concordant  increase  in  cerebral 
blood  volume  (CBV)  and ICP.  Opioid  induced  increases  in  ICP  can  be 
avoided simply by controlling MAP during opioid administration. As a result, 
opioids are unlikely to be an issue during maintenance with respect to brain 
bulk. 
Mannitol  reduces  brain  bulk  by  creating  an  osmotic  gradient 
across the blood brain barrier causing water to flux from the extracellular 
extravascular  to  intravascular  compartments.  There also  is  evidence  that 
mannitol improves  deformability  of  red blood  cells,  thereby  reducing 
viscosity promoting increased blood flow. As a result, autoregulation causes 
vasoconstriction that may reduce CBV. Mannitol is best given around time of 
skin incision  (typically  0.5  mg•kg-1)  so  the  peak effect  becomes available 
upon dural opening. Additional mannitol may be of value if the brain is still 
"tight". 
 If hypercapnia is present it should be corrected. The response of 
the cerebral vasculature to changes in PaCO2 is rapid. There has been a major 
shift in attitude regarding the value of hypocapnia with the preponderance of 
opinion being that a major reduction in PaCO2 poses the risk of secondary 
ischemic  injury.  Stabilizing  the PaCO2 in  the  range  of  30–35  mmHg  is 
usually adequate. 
Administration of thiopental in large doses cause major reduction 
in metabolic rate and a coupled reduction in CBF. This can be effective but 
will likely prohibit adequate neurologic evaluation upon emergence. 
Lumbar  cerebrospinal  fluid  (CSF)  drains  are  often  placed  for 
aneurysm surgery. The volume drained often exceeds 100 mL making this 
technique perhaps the most effective in reducing brain bulk of all options. 
The  goal  in  aneurysm  surgery,  however, is  different  from  that  of  tumor 
surgery.  In  most  aneurysm cases, reduction in  brain bulk is  performed to 
reduce the magnitude of retractor pressure required to expose the aneurysm at 
the base of the brain. CSF drainage is usually not employed until after the 
dura is opened. This is because rapid and profound reduction in brain bulk 
can tear  veins  draining into sinuses. An acute  subdural  hematoma can be 
formed if the drain is opened prior to surgical exposure of the brain with little 
hope of prompt hemostasis. Practical approaches to this is to ensure patency 
of the drain after positioning by observing progression of the air/fluid level 
through the connected catheter (usually less than 1 mL of CSF drainage is 
required  to  confirm  this)  and  then  leave  the  drain  closed  until  surgical 
requirements dictate that it be opened. CSF drains are rarely used for most 
types  of  tumor  surgery  because  of  fear  of  transtentorial  herniation. 
Occasionally CSF drains are placed for transphenoidal pituitary surgery, not 
to drain CSF, but to allow injection of saline or air to force the tumor towards 
the sphenoid sinus to facilitate surgical excision. 
Management of ventilation 
The classic  reflex when confronting a patient  with intracranial 
hypertension is use of hyperventilation. This is derived from knowledge that 
alteration of PaCO2, within the range of approximately 20–80 mmHg, causes 
parallel  changes  in  CBF.  CBF,  in  fact, is  only  a  surrogate  for  the  true 
determinant of ICP, that being CBV. CBF is easy to measure while CBV is 
not  (particularly  in humans).  It  is  logical,  however,  that  given  a  constant 
MAP, PaCO2 induced changes in CBF should correlate with cross-sectional 
diameter  of  the  cerebral  arterial  vasculature.  Decreasing  PaCO2 results  in 
decreased  CBF  and  it  is  presumed  that  this  also  causes decreased  CBV. 
Indeed, there is abundant clinical evidence in patients with ICP monitors in 
place, that reduction of PaCO2 results in at least transient reduction in ICP. 
Neuroanesthetic practice,  therefore,  had  been to  cause  large  reductions  in 
PaCO2. Data  from head injury patients  has caused a major change in this 
perspective.  Use  of  retrograde  jugular  venous  hemoglobin-O2 saturation 
measurement techniques has repeatedly shown that reduction in PaCO2,  in 
fact,  can  exacerbate  cerebral  hypoperfusion.  As  a  result,  it is  no  longer 
advocated that major reductions in PaCO2 be made in patients undergoing 
craniotomy for space occupying lesions. Modest reductions in PaCO2 remain 
valuable, however, to counteract vasodilatory effects of volatile anesthetics. 
It  is  also  important  to  recognize  the  value  of  end-tidal  CO2 
monitoring  during  craniotomy.  This  advance  has  reduced  the  need for 
repeated arterial blood gas sampling. However,  analysis of arterial to end-
tidal CO2 gradients in neurosurgical patients has shown that the gradient is 
not  always  predictable  and  should be  measured  for  the  individual  patient 
when management of intracranial hypoperfusion is a concern. 
Muscle relaxants 
Several  muscle relaxants have received special  consideration in 
the context of craniotomy. The most interesting is succinylcholine. There is 
clear  evidence  from  both  experimental  animals  and  humans that 
succinylcholine  can  increase  ICP  under  conditions  of  intracranial 
hypertension. The magnitude of increase is typically small and transient. The 
mechanism was originally thought to be attributable, not to succinylcholine, 
but rather preservatives used in its formulation. It has been shown in humans 
that  ICP  changes  caused  by  succinylcholine  can  be blocked  by  pre-
administration of a defasciculating dose of non-depolarizing relaxants. This 
suggests that fasciculations resulting from succinylcholine play a role in the 
ICP effects of this drug.  A probable mechanism is the massive fasciculation-
induced afferent barrage from muscle spindles to the brain that cause transient 
increases in metabolic rate  and coupled increases in CBF. Common sense 
plays a major role in the decision whether to use succinylcholine in patients 
with  intracranial  hypertension.  Pretreatment  with  a  small  dose of  a  non-
depolarizing agent most likely makes the argument moot. At the same time, 
emergency airway management and the clear desire to minimize hypercapnia 
and  hypoxemia  in  patients  with traumatic  brain  injury  (TBI)  dictate  that 
succinylcholine can be an appropriate adjunct for tracheal intubation until a 
relaxant with similar speed of onset and duration of action is introduced to 
clinical practice. 
There  is  clear  evidence  that  the  duration  of  action  of  non-
depolarizing muscle  relaxants  are  reduced  by  a  variety  of  anti-convulsant 
medications. Even short durations of exposure to anti-convulsants can elicit 
this change. The mechanism for this remains unclear. Most patients requiring 
craniotomy  are  being  treated  with  anticonvulsants. As  a  result,  the  non-
depolarizing  relaxant  dosing  regimen  will, probably,  require  alteration. 
Atracurium and cis-atracurium seem to be largely resistant to these effects, 
most likely because metabolism is achieved by Hoffman elimination. 
Management of temperature 
There  has  been abundant  enthusiasm over  the  past  decade  for 
routine use of intra-operative hypothermia in patients requiring brain surgery. 
This is based on overwhelming laboratory evidence that reduction of body 
temperature  by  even  2–3°C  can cause  major  neuroprotection.  Several 
problems remain before strong advocacy can be made for routine practice of 
induced hypothermia.  First,  there  is  virtually  no  evidence  of  mild 
hypothermia efficacy in humans. An appropriately powered trial in patients 
(with TBI) failed to define benefit and in fact identified worsened outcomes 
in the elderly. Despite considerable effort,  there remains no clear evidence 
that  induced  hypothermia  is  neuroprotective in  cardiac  surgical  patients. 
Finally, there is increasing evidence that mild hypothermia poses a variety of 
risks  to  the  general surgical  population.  The  International  Hypothermia 
Aneurysm Surgery  trial  is  currently  being  conducted  with  1,000  patients 
being  randomized  to  normothermia  (36.0–37.0°C)  or hypothermia  (32.5–
33.5°C) during intracranial aneurysm surgery. 
Pharmacological neuroprotection 
A  holy  grail  of  academic  neuroanesthesia  has  been  the 
demonstration of neuroprotective efficacy of anesthetics and other purported 
neuroprotective  compounds.  The  simple  interpretation  of  four decades  of 
research is  that  we still  lack definitive proof (particularly in humans) that 
pharmacological neuroprotection is a reality. Because most anesthetics reduce 
brain metabolic requirements, it certainly makes sense that in the context of 
diminished substrate supply anesthetics will increase tolerance to ischemia. 
However, the issue is now recognized to be far more complex than this logic. 
More important, other than a few studies examining barbiturates in cardiac 
surgical patients, there are no human studies that have prospectively defined 
presence or absence of neuroprotection from anesthetics. 
Laboratory studies have now irrefutably shown that anesthetics 
increase tolerance of brain to ischemia. This is independent of the type of 
ischemia (global vs. focal). The mechanisms are likely related to inhibition of 
glutamatergic (excitatory) neurotransmission and potentiation of GABAergic 
(inhibitory)  neurotransmission. Many  anesthetics  meet  these  criteria  (i.e., 
volatile  agents, propofol,  barbiturates).  Other  compounds  such  as  nitrous 
oxide and opioids appear to be inert. It is clear that animals sustaining stroke 
while  awake  have  larger  resultant  lesions  than  if  anesthetized. But  which 
anesthetic  is  superior  to  another  remains  controversial. Many  clinicians 
persist  in use of  thiopental  as a  first  line agent.  The logic for  this is  that 
thiopental has the longest track record of experimental efficacy and there is 
one  human cardiac  surgical  trial  that  found  benefit  (albeit  small).  It is 
difficult, therefore, to recommend one agent as being superior to the others. 
There is  one exception to this conclusion and that  is  etomidate.  Although 
outcome evidence is not available, human studies have provided reasonable 
evidence that etomidate may exacerbate injury. 
As a result of incomplete science regarding anesthetic efficacy in 
humans, and in the absence of any other drugs approved for the purpose of 
neuroprotection  in  humans,  the  anesthesiologist is  left  with  a  speculative 
practice when providing pharmacological neuroprotection. Perhaps the best 
we can do for the patient, with certainty, is to provide oxygenated blood at a 
sufficient perfusion pressure with simultaneous control  of  temperature and 
glucose concentration. 
Management of emergence 
If  failure  to  emerge  is  attributable  to  surgery,  a  computerized 
tomographic scan is usually performed to rule out hematoma formation. In 
contrast, if the problem is anesthesia based, patience in allowing elimination 
of anesthetic agents (or use of opioid antagonists or reversal of neuromuscular 
blockade) is the solution and the surgeon should be counseled that anesthesia 
is a likely explanation. Therefore, when planning the anesthetic, it is helpful 
to restrict use of agents to those that can be monitored for concentration or 
those  for  which sufficient  knowledge of pharmacodynamics allows highly 
probable  clearance  by  the  time emergence  is  desired.  As  an  example, 
induction doses of thiopental or propofol are unlikely to relate to failure to 
emerge from a three- to four-hour procedure.  In contrast,  persistent  blood 
propofol  concentrations  sufficient  to  prevent  awakening  after a  prolonged 
infusion may be difficult to diagnose.  
Neuromuscular  blockade is  maintained until  completion  of  the 
head dressing. Elimination of volatile anesthetics can be initiated at the time 
of  bone flap  replacement.  Anesthesia  is  maintained  by  either  residual 
concentration of opioid (i.e., fentanyl or sufentanil) or continued infusion of 
remifentanil. Supplementation with nitrous oxide is likely superior over use 
of  IV agents  because  its  concentration can  be  defined  by  end-tidal  gas 
analysis, which aids in defining failure to emerge. Rapidly cleared IV agents 
such as lidocaine can be of value in sustaining anesthesia for a few additional 
minutes. If remifentanil is used, the rate of infusion can remain unchanged 
until the dressing is complete. This supports anesthesia during placement of 
the dressing but still allows a prompt and reliable emergence. It is important, 
however,  to  provide  transitional analgesia  before  discontinuation  of 
remifentanil. Administration of 10 mg morphine or 100–150 µg fentanyl (in 
adults) is usually sufficient to provide analgesia without altering predictability 
of emergence. 
Patients undergoing craniotomy may exhibit hypertension during 
emergence that is sustained through the early phases of recovery. Because of 
the  implications of  intracranial  hemorrhage,  it  is  imperative  to  plan  for 
treatment of hypertension before it becomes manifest. Prophylactic doses of 
labetolol are helpful, usually requiring 40–60 mg to be effective. It has not 
been proven that emergence hypertension contributes to hematoma formation. 
It has been shown, however, that many patients who develop postoperative 
haematomas have had episodes of hypertension during emergence or early 
recovery. The source of hemorrhage is almost always within the surgical field 
and thus quality of hemostasis undoubtedly is important. However, because 
the  mortality  associated  with  postoperative hematoma  formation  requiring 
emergent evacuation is high, it seems incumbent on the anesthesiologist to 
seriously attend to management of hemodynamics during emergence. 

α2-Adrenoceptor pharmacology 
Awakening of interest in a sub classification of α-adrenoceptors was foreseen in 
1969 as a means to explain the regulation of the release of nor- adrenaline, from which it was 
inferred  that  a  α-receptor  was  located  presynaptically.  This  led  to  a  reclassification  of  α-
adrenoceptors, based on their synaptic location, into postsynaptic α1, and presynaptic α2. As more 
selective  α-adrenoceptor  antagonists  became  available  it  was  possible  to  separate  the  α-
adrenoceptors into two subtypes based on the receptor response to the antagonists prazosin (α1) 
and yohimbine (α2). This classification was further expanded as the result of radioligand binding 
and molecular biological techniques.
Adrenoceptor  ligand techniques  have at  present  identified four α2-isoreceptors. 
Kobilka  et  al  and  Regan et  al  cloned the  genes  encoding α2-adrenoceptors  from the  human 
platelet and the human kidney and produce functional α2-receptors. The α2A-receptor corresponds 
lo  the  platelet  α-receptor,  which  has  been  gene  mapped  to  chromosome  10.  The  kidney 
isoreceptor maps to chromosome 4.
It  seems  that  the  anaesthetic  effects  of  α2-agonists  are  subtype-specific.  Although  the 
adrenoceptor  subtype  transducing  the  central  hypnotic  action  has  not  yet  been  identified, 
radioligand techniques have identified the receptor subtype in human spinal cord as α2A . Millan 
showed that specific α2A antagonists only reversed the analgesic effects of α2A-agonists in the 
spinal cord. 
The α2-adrenoceptor is a member of the family of G coupled membrane receptors. 
The subtypes of the adrenoceptors are homologous in that they have a common long chain of 
amino acids between 415 and 480 amino acids in length, with seven transmembrane hydrophobic 
domains that are connected by loops which project into either the cytoplasm or the extracellular 
space and straddle the lipid membrane.  Affinity labeling studies with α2-adrenergic receptors 
employing  antagonist  and  agonist  ligands  suggest  that  it  is  the  fourth  membrane-spanning 
domain, which is involved with ligand binding. Differentiation of α1 from α2-receptors depends 
on the configuration of the rather shorter cytoplasmic tail. 
α2-adrenoceptors  activate  the  Gi protein,  which  carries  the  suffix  i  because  it 
inhibits  adenylyl  cyclase  and  so  prevents  an  increase  in  cyclic  adenosine  monophosphate 
(cAMP)  levels.  The  activated  α2-adrenoceptor  produces  its  effects  by  at  least  five  different 
mechanisms, the main one being the inhibition of adenylyl cyclase and the decrease in cAMP 
levels.  This  may however  be  only a  permissive  role  as  the  decrease  in  cAMP alone  is  not 
adequate to produce many of the effects of the α2- agonists. The extrusion of protons is increased 
by accelerating Na+/H+ exchange in the platelet  by α2-receptor  activation; calcium entry into 
nerve channels may be decreased and phosphatidyl inositol metabolism may be affected. The 
inhibitory (G) protein can also activate a variety of ion channels, such as the K+ channel in cell 
membranes. Evidence that dexmedetomidine acts by modifying the function of K+ channels is 
based on the ability of pertussis toxin (a selective inhibitor of the Gi protein) or 4-amino pyridine 
(which blocks the K channel) to inhibit the effects of dexmedetomidine in a dose- dependent 
manner.
Clonidine 
Clonidine is  the prototype α2-adrenoceptor agonist  which has been extensively 
studied in animals and humans, but it is only a Partial agonist with a ratio of 200: 1 (α2: α1 ) its 
action is limited at higher doses by the ceiling effect. Clonidine is an imidazoline compound. 
Receptors distinct from the α2-receptor, which bind imidazolines and oxazolines (e.g. idazoxan 
and rilmenidine) have been identified.  These receptors have been named the I receptors and 
classified into two subtypes — I1 and I2. I1 receptors appear to be confined to the brain, whereas 
I2 receptors are found in the brain, in the pancreas (activated by a K+ channel, and involved in 
insulin release) and in the kidney. Many drugs act on the α2-receptor and the I1 receptor to a 
greater  or  lesser  extent  those  having  a  predominant  effect  on  the  I1 receptor  (clonidine  < 
moxonidine < rilmenidine) produce centrally mediated hypotension, but the I1 agonists do not 
produce sedation. 
Clonidine  can  be  administered  orally,  intravenously,  intramuscularly, 
transdermally, epidurally and intrathecally. Clonidine is lipid-soluble, rapidly absorbed orally, 
and reaches a peak plasma level within 60—90 mm. The elimination half-life is 9—12 h; about 
50% is metabolized in the liver to inactive metabolites, and the remainder is excreted unchanged 
in the kidney.[3]
Dexmedetomidine 
Dexmedetomidine is a more selective and specific α2-adenoreceptor agonist than 
clonidine, with an affinity for the α2-adrenergic receptor eight times that of clonidine,[59]
-although even it may bind to α1-adrenoceptors at very high doses and attenuate its α2 action. 
Dexmedetomidine  is  the  dextrostereoisomer  and  pharmacologically  active   component  of 
medetomidine,  which  is  used  in  veterinary  practice;  both  drugs  are  imidazoles. 
Dexmedetomidine is a potent drug and produces significant effects at plasma concentrations of 
less than 1.0 ng/ml. Its volume of distribution and clearance are similar to those of fentanyl, 
although its pharmacokinetics is complex; dexmedetomidine exhibits a concentration-dependent 
non-linear  pharmacokinetic  profile.[61]  At  high  concentrations  its  volume  of  distribution  is 
decreased due to peripheral vasoconstriction, therefore intravenous dexmedetomidine should not 
be given rapidly. An oral preparation given to animals avoids the transient rise in blood pressure 
that  occurs  after  intravenous  injection  of  dexmedetomidine  in  some  animal  studies  and  in 
humans.[5]  A  sublingual  preparation  is  not  yet  available  but  would  allow  preoperative 
administration, without he discomfort of an intramuscular injection or the uncertain absorption of 
an oral dose.
Mivazerol 
Mivazerol  is  the  most  recent  α2-agonist  to  be used clinically,  and is  currently 
being assessed for its anti-ischaemic effects rather than its sedative or anaesthetic effects.[20] 
Reversal 
The  anaesthetic  action  of  the  α2-adrenoceptor  agonists  can  be  reversed  by 
centrally  acting  α2-antagonists  such  as  atipamezole  and  idazoxan,  but  not  by  peripheral  α2- 
antagonists that do not cross the blood brain barrier. α2-antagonists are not yet routinely used in 
human anaesthesia, but atipamezole has been tested in human volunteer clinical trials and well 
tolerated.[35]
Sites of action 
The use of radioligands has allowed auto radiographic mapping of the locations of 
α2-adrenoceptors within the central nervous system. The locus coeruleus in the upper brainstem 
has been identified as a major site for the hypnotic action of the α2-agonists. The locus coeruleus 
(LC; sky-blue spot) is a small but very important neuronal nucleus situated bilaterally in the floor 
of the fourth ventricle. It has major afferent connections from the rostral ventrolateral  medullary 
nuclei. It has three important sets of efferent connections: 
I. Noradrenergic fibers, which connect with the subthalamic, relay nuclei and the thalamus, with 
consequent effects on cortical activity. 
2. Fibres to the descending reticular formation with connections to the pressor and depressor 
areas of the vasomotor centers. 
3. Descending fibers in the reticulospinal tracts, which inhibit pain transmission at a spinal level. 
The rate of spontaneous discharge of the LC neurons correlates with the level of 
arousal and vigilance, and is lowest during rapid eye movement sleep. Opioids acting through μ-
receptors and α2-adrenoceptor agonists hyperpolarize and silence LC neurons, the former acting 
through chloride channels and the latter through potassium channels sensitive to suppression by 
pertussis toxin producing in animals a dose-dependent state resembling sedation and anaesthesia. 
Clonidine  markedly  decreases  the  noradrenaline  concentration  in  the  LC.  Dexmedetomidine 
injected directly into the LC produces a dose- dependent hypnotic response in awake rats, while 
injections made 2 mm lateral to the LC had no effect. If the α2-adrenoceptor subtype in the LC 
can be identified, more specific drugs could be developed and targeted at the desired effects of 
sedation and anaesthesia. 
High densities of α2-agonist binding sites have been observed in the dorsal motor 
nucleus of vagus nerve which may be the site of the bradycardic and hypotensive effects of the 
α2-agonists, although other studies suggest that these receptors are more susceptible to agonists 
In human spinal cord high densities of α2-adrenoceptors have been shown in the 
intermediolateral cell column and the substantia gelatinosa.
Mechanisms of analgesic action 
α2-Adrenoceptors are found postjunctionally on the dorsal  horn neurons of the 
spinal  cord  and may act  by inhibiting  the  release  of  neurotransmitters  such  as  substance  P. 
Noradrenergic  neurons  in  several  brainstem  nuclei  descend  to  these  dorsal  horn  neurons; 
nociceptive signal transmission by this pathway can be inhibited by the application of α2-agonists 
centrally to the brainstem nuclei. Other mechanisms of analgesic action by the α2-adrenoceptor 
agonists may include interaction with cholinergic, purinergic and serotonergic pain systems. 
Radioligand studies have shown that μ opioid receptor distribution overlaps that 
of  α2-adrenoceptors  in  the  dorsal  horn  area  and in  the  LC.  This  relationship  appears  to  be 
functional as well  as anatomical as there is a great deal of evidence,  both experimental  and 
clinical,  to  show  that  α2-agonists  and  opioids  given  together  into  the  spinal  cord  act 
synergistically  to  reduce  pain.  Co  administration  of  low  doses  of  dexmedetomidine  and 
morphine  (μ-agonist)  produce  a  synergistic  inhibition  of  C-fiber  responses  but  not  Aβ-fibre 
evoked responses, suggesting that the interaction is selective to afferent pain fibers, presynaptic 
to the dorsal horn neurons. The synergism is mediated through the μ opioid receptor but not the 
δ-receptor and can be reversed by either naloxone or atipamezole. The mechanism of synergism 
may be through some sort of convergence of each receptor type on G protein- mediated second 
messenger channels able to regulate K+ and or Ca2+ channels.
Receptor interactions 
The α2-agonists and the benzodiazepines both produce sedation and anxiolysis. 
The  effect  of  these drugs  when administered  together  is  greater  than  that  expected  from an 
additive  response.  Application of  specific  antagonists  (atipamezole  — dexmedetomidine and 
flumazenil — midazolam) does not reverse the action of the other class of drug. It is unlikely that 
this  synergism is due to a drug kinetic effect  or to direct  receptor interaction; it  seems it  is 
exerted at a pre- or post receptor locus. 
The  α2-adrenoceptor  agonists  also  interact  with  transmembrane  calcium 
movement.  Verapamil,  a calcium-channel  blocker,  significantly enhanced the duration of the 
hypnotic—anaesthetic  action  of  dexmedetomidine,  while  a  calcium-channel  agonist  (BAY 
K8644)  reduced  the  hypnotic—anaesthetic  properties  of  dexmedetomidine.  The  interaction 
between the α2-agonists and calcium- channel blockers may be due to co activation of different 
subtypes of calcium channel. 
Physiological effects of the α2-adrenoceptor agonists 
Central nervous system 
The α2-adrenoceptor agonists produce dose-related sedation, anxiolysis, analgesia, 
and a reduction in the requirements for other anaesthetic agents. They also reduce intraocular 
pressure. 
Respiratory effects 
The effects of the α2-adrenoceptor agonists on the respiratory system appear to be 
mild. Infusions of increasing levels of dexmedetomidine in healthy volunteers produced dose-
related  sedation  and  sleep,  with  a  slight  increase  in  Paco2,a  decrease  in  minute  ventilation 
characterized by a reduction in tidal volume and little change in respiratory rate. No significant 
oxyhaemoglobin  desaturation  occurred.  At  all  dose  levels  up  to  2  μg  kg-1 the  hypercapnic 
ventilatory response slope was decreased slightly; there was an unexplained initial increase in 
oxygen consumption. In dogs an initial dose of dexmedetomidine 1 μg kg-1 decreased resting 
ventilation  but  higher  doses  progressively  increased  resting  ventilation  even  though  the 
hypercapnic  ventilatory response  was  decreased  at  doses  higher  than  10  μg kg-1.  Nebulized 
clonidine has been shown to reduce bronchoconstriction produced by histamine in asthmatics. 
Cardiovascular responses 
Postjunctional α2-adrenoceptors are located on human resistance and capacitance 
vessels where they mediate constriction. The effects of  α2-constriction differ from α1 effects in 
that they are slower in onset, longer-lasting, and more sensitive to pH and temperature changes 
and may require angiotensin II for their expression. Pressor responses to α2-agonists are more 
sensitive to blockade by calcium antagonists than those induced by α1-agonists, as α1 activation 
not only produces extracellular calcium influx, but also induces intracellular calcium release.[31] 
Two  predominant  haemodynamic  effects  occur  when  α2-agonists  are  given 
intravenously.  There  is  an  initial  short-lived  increase  in  blood  pressure,  systemic  vascular 
resistance and a concurrent decrease in cardiac output due to activation of the Postjunctional α2-
receptors on the peripheral vasculature. This is accompanied by a decrease in heart rate, and 
followed by a longer-lasting decrease in blood pressure and heart rate resulting from a centrally 
mediated decrease in sympathetic tone and an increase in vagal activity.[14]
The exact site of action for the central hypotensive effect is not yet known. There 
are α2-receptors in the nucleus tractus solitarius and the lateral reticular nucleus, and the pressor 
response  mediated  by  the  LC  is  inhibited.  Clonidine  has  little  effect  on  blood  pressure  in 
hypertensive  tetraplegic  patients  in  whom  central  sympathetic  control  has  been  lost.  The 
hypotensive action of the α2 agonists is not attenuated by depletion of catecholamines within the 
brain, suggesting that the hypotensive effect is a direct postsynaptic α2 action. It seems that the 
imidazole-preferring  receptors  are  important  in  mediating  the  hypotensive  effects  of  the  α2-
agonists.  The  α2-agonists  appear  not  to  affect  baroreceptor  reflex  gain,  but  to  reset  them to 
operate at a lower blood pressure level. 
There  is  evidence  to  suggest  in  experimental  animals  that  the  bradycardia  is 
mainly produced by a central action of the α2-agonists: L659,O66 an α2-antagonist that does not 
cross the blood brain barrier, reversed the hypertensive response to dexmedetomidine infusion 
but had no effect on the reduction in heart rate, while atipamezole, an α2-antagonist that does 
cross the blood brain barrier, reversed the effects of dexmedetomidine on heart rate. There may 
also be a vagomimetic effect or a presynaptically mediated reduction in noradrenaline release, as 
the bradycardiac effect is sustained in tetraplegic patients.[34]
Although the α2-agonists  can cause bradycardia,  they can protect  against  other 
arrhythmias; dexmedetomidine prevented adrenaline-induced arrhythmias in dogs anaesthetized 
with halothane.
Coronary vasculature 
Application of α2-adrenoceptor agonists to coronary may cause vasoconstriction 
maximized   by inhibition  of  nitric  oxide  synthesis  by  NG nitro-L-arginine  methyl  ester  (L-
NAME).  The  α2-adrenergic  antagonist  atipamezole  blocked  the  contractile  response  to  low 
concentrations  of  dexmedetomidine  in  proximal  but  not  distal  coronary  artery.  suggesting 
predominance of α2 receptors proximally. Experimental work in animals may not be applicable 
in humans as there is considerable interspecies variation in the existence and distribution of α2-
isoreceptors in the coronary circulation.[43]
There  are  no  postsynaptic  α2-adrenoceptors  in  the  myocardium  but  there  are 
presynaptic  α2-receptors  modulating  noradrenaline  release.  Information  derived  from  the 
responses of isolated ventricular myocardium suggests that the decrease in cardiac output seen 
after  the  infusion  of  α2-agonists  is  not  due  to  an  intrinsic  myocardial  contractile  action  but 
secondary  to  the  increase  in  systemic  vascular  resistance  produced  by  peripheral  α2 
vasoconstriction.[43]
Effects on cerebral blood flow and intracranial pressure 
Both  cerebral  blood  flow  (CBF)  and  cerebral  metabolic  rate  of  oxygen 
consumption  (CMRO2)  decreased  when  dexmedetomidine  was  given  during  halothane 
anaesthesia  in  mechanically  ventilated  dogs.  Similar  responses  were  found  when 
dexmedetomidine was used with isoflurane, although CMRO2 did not change. In neither study 
was  there  evidence  of  global  ischaemia.  In  both  studies  dexmedetomidine  reduced  MAC; 
therefore one mechanism of the reduction CBF may be prevention of the vasodilating effect of 
the volatile agents. An increase in cerebrovascular resistance mediated through the postsynaptic 
α2-receptors is also possible.[46]  
Endocrine effects 
Insulin  release  is  inhibited  by  a  direct  action  on  the  β-cells  of  the  islets  of 
Langerhans.  Although  hyperglycaemia  has  been  reported  in  animals  given  α2-agonists,  in 
humans  this  does  not  appear  to  be  a  clinical  problem.  The  release  of  growth  hormone  is 
enhanced and lipolysis  in  adipose  tissue  is  inhibited.  Those  α2-agonists  with  an  imidazoline 
structure can inhibit steroidogenesis.[4]
Renal effects 
Diuresis  is  a  noticeable  effect  of  the  α2-agonists  produced  by  a  variety  of 
mechanisms, although the relative importance of each is not yet clear. Clonidine inhibits the 
release  of  antidiuretic  hormone  in  dogs  and  decreases  the  levels  of  vasopressin  in  human 
cerebrospinal fluid. The renal tubular action of antidiuretic hormone is blocked by α2-agonists 
and there may also be an increase in glomerular filtration rate. Azepexole inhibits the release of 
renin through receptors on the juxtaglomerular apparatus in an isolated perfused kidney. Another 
mechanism of action that has been investigated is the release of atrial natriuretic factor.
Other important physiological actions
They  produce  dry  mouth  due  to  reduced  salivation.  There  is  a  decrease  in  vagally 
mediated bowel motility and secretion throughout the gastrointestinal tract although there is no 
effect on gastric pH. Clonidine has been used to teat watery diarrhea. The  α2– adrenoceptors on 
human platelets have been implicated in platelet aggregation.

Alpha 2 Adrenergic Agonists and Anaesthesia
Introduction 
The anaesthetic use of α2-adrenergic receptor agonists has been of considerable 
and sustained interest for the last 15 years. Clonidine, the archetype but not the most selective, is 
nowadays familiar to many anaesthetists. The different sedative, haemodynamic and analgesic 
properties of these agents  is  however  confusing and the exact  role of α2-adrenergic  receptor 
agonists  and  especially  clonidine,  remains  a  matter  of  debate  and  poorly  defined  despite 
considerable clinical evidence (1). Based on this evidence we can nevertheless identify when α2-
adrenergic receptor agonists can be valuable in perioperative management.
α2- adrenergic agonists cause
1.dose  related sedation
2.anxiolysis
3.reduction of  secretions
4.peri  operative hemodynamic stability
5.  analgesia
6.reduction in requirements for opioids and other anaesthetic agents
Premedication 
α2-adrenergic  receptor  agonists  cause  sedation  by  stimulation  of  the  locus 
coeruleus,  a  nucleus  of  the  medulla  involved  in  the  sleep-wake  cycle  (2).  Sedation  is  by 
stimulation  of  specific  α2 adrenergic  receptors  coupled  with  a  G  protein,  leading  to  cell 
membrane hyperpolarisation. The sedative effect of α2-adrenergic agonists is antagonised by   α2 
adrenergic agonists, explaining why less selective agents, such as clonidine, which has some a1 
stimulatory activity, do not achieve complete anaesthesia. Because of their sedative effect, α2-
adrenergic  agonists  can  be  used  as  premedicants  and,  in  addition,  can  have  an  anaesthetic-
sparing effect during anaesthesia. α2-adrenergic agonists reduce the dose of intravenous hypnotic 
needed  for  anaesthetic  induction  and  orotracheal  intubation,  and  reduce  the  MAC  of  co-
administered  volatile  anaesthetic  agents.[49]  Sedation  is  associated  with  mild  respiratory 
depression, which might be more serious in high-risk patients. Clonidine has been recommended 
as premedication in a dose of 1-3 mcg/kg. Dexmedetomidine is a more selective α2-adrenergic 
agonist  with the same effects  and a  marked anaesthetic sparing effect  during surgery.[62]  If 
induction agent doses are not reduced, both drugs may cause hypotension at the induction of 
anaesthesia, and increase the incidence of bradycardia during anaesthesia. Because of these side 
effects, some anaesthetists are reluctant to give α2-adrenergic agonists as premedication. There 
are some exceptions where they could be very suitable:
•  Drug addicts  and alcoholics  give problems such as  withdrawal  symptoms,  and the risk of 
increased sympathetic activity in cocaine users. Sympathetic hyperactivity caused by cocaine is 
well  controlled  by  α2-adrenergic  agonists.  Clonidine  is  a  classic  treatment  for  opioid  and 
alcoholic  withdrawal.  Given  as  premedication  and  continued  after  operation,  α2-adrenergic 
agonists reduce the risk of withdrawal.[7]
• Chronic pain and palliative care patients are often receiving large doses of opioids and have 
greater  perioperative  opioid  needs,  that  can  be  markedly  reduced  by  α2-adrenergic  agonist 
premedication. 
• Hypertensive patients are particularly vulnerable to swings in blood pressure during surgery 
and premedication with α2-adrenergic agonists is a useful, and under-utilised, means of reducing 
this  hyper-reactivity.  Obviously  those  few  patients  still  receiving  long-term  treatment  for 
hypertension  with  α2-adrenergic  agonists  must  not  have  it  stopped  peroperatively.  In  such 
patients clonidine forms an essential part of their premedication.
Control of haemodynamic instability and prevention of myocardial ischaemia 
and related cardiac complications 
The  haemodynamic  effects  of  α2-adrenergic  agonists  are  both  peripheral  and 
central. Stimulation of subendothelial receptors causes vasoconstriction.
Conversely,  stimulation  of  α2-adrenergic  receptors  of  neurons  in  the  nucleus 
tractus  solitarius  augments  the  inhibition  by this  nucleus  of  the  sympathetic  neurons  of  the 
medulla.  In  this  way,  alpha  adrenergic  agonists  reduce  the  tonic  activity  of  the  baroreflex, 
decreasing arterial pressure and causing bradycardia. On the other hand the phasic activity of the 
baroreflex is preserved or even improved, so that any decrease in arterial pressure is followed by 
a significant increase in heart rate and any increase in arterial pressure is better controlled by a 
consequent  bradycardia.  In  addition,  α2-adrenergic  agonists  depress  presynapic  sympathetic 
neurons  in  the  lateral  horn  of  the  thoracic  spinal  cord.  This  effect  is  reversed  by the  local 
administration of cholinesterase inhibitor neostigmine. Consequently, intrathecal administration 
of  α2-adrenergic  agonists  causes  more  marked  hypotension  than  parenteral  administration. 
Finally,  hypotension  and  bradycardia  induced  by  α2-adrenergic  agonists  are  reversed  by 
ephedrine and atropine respectively but large doses are required.
In both healthy volunteers and patients, α2-adrenergic agonists decrease plasma 
catecholamine levels. Giving α2-adrenergic agonists before anaesthesia decreases cardiac output, 
vascular resistance, cardiac preload, afterload and contractility. Conversely, during anaesthesia, 
clonidine or dexmedetomidine increase cardiac output by improving cardiac loading conditions. 
In addition α2-adrenergic agonists prevent hypertension and tachycardia on intubation and during 
surgical stimulation. However hypotension and bradycardia occur more frequently in patients 
after clonidine, dexmedetomidine or mivazerol. During recovery from anaesthesia, these agents 
prevent  tachycardia  and hypertension,  decrease the incidence of shivering,  and reduce VO2. 
Given  as  50  mcg  doses,  a  dose  of  up  to  150 mcg will  suppress  postoperative  shivering  in 
approximately 90% of cases in less than 5 minutes. Clonidine, dexmedetomidine and mivazerol, 
in patients at risk during cardiac or vascular surgery, may provide better haemodynamic control 
and prevent myocardial ischaemia. In patients such as those with documented coronary artery 
disease undergoing vascular surgery, mivazerol reduces cardiac morbidity and mortality.
Postoperative analgesia and regional anaesthesia 
α2-adrenergic  agonists  inhibit  transmission of  nociceptive stimuli  in  the dorsal 
horn  of  the  spinal  cord.  Their  effect  mimics  that  of  noradrenalin  released  by  inhibitory 
descending pathways. Noradrenaline inhibits the evoked activity of wide dynamic range neurons 
and  causes  analgesia  in  laboratory  animals.  Moreover  α2-adrenergic  agonists  increase  the 
analgesic effect of opiates and interact with cholinergic neurons to do so. They augment local 
anaesthetic  blockade  and  prolong  duration.  Clonidine  has  been  used  by  epidural,  spinal, 
perineural, intra-articular and parenteral routes to obtain postoperative analgesia.
Central Nerve Blocks
Because of its analgesic action in the spinal cord, clonidine was initially given 
either by the epidural or intrathecal routes. Epidural or intrathecal clonidine is not neurotoxic and 
thousands of patients have received the drug by these routes without neurological complication. 
However, because of the large epidural doses that are necessary to obtain long-term analgesia 
(up to 2-3000 mcg per 24 H for the epidural route!) sedation, hypotension and bradycardia are 
common.  The use of epidural  clonidine as  the sole  analgesic  agent  is  thus  not  popular,  and 
combination  of  epidural  clonidine  with  either  opioids  and  /  or  local  anaesthetics  is  more 
commonly used for postoperative analgesia. Even here, the dose should be limited to between 10 
and 15 mcg/kg/hour to avoid side effects.[24]
Compared  with  morphine,  intrathecal  clonidine  produces  analgesia  of  shorter 
duration  but  without  the  associated  risk  of  respiratory  depression  or  urinary  retention.  In 
association  with  local  anaesthetics  the  maximum dose  of  intrathecal  clonidine  is  1  mcg/kg. 
Giving  clonidine  with  a  local  anaesthetic  improves  the  quality  and  duration  of  the  block, 
minimises the pain of the tourniquet during lower limb surgery,  and prevents shivering. The 
quality  of  spinal  anaesthesia  during  lower  limb  orthopaedic  surgery  using  a  tourniquet  is 
considerably improved and prolonged by adding of clonidine to the local anaesthetic solution. 
Caesarean section under spinal anaesthesia is another good indication for intrathecal clonidine.
Caudal clonidine combined with local anaesthetics in children is potentially very 
useful and increases the duration of anaesthesia and analgesia by a factor of 2 or 3 without 
haemodynamic side effects. The dose is between 2 and 3 mcg/kg.[26]
Either epidural and intrathecal clonidine have been suggested for alleviation of 
labour pain, with clonidine given either alone or in combination with intrathecal sufentanil or 
epidural bupivacaine. Clonidine crosses the placenta but no adverse effect has been documented 
in the new-born. To avoid hypotension and bradycardia in the mother and in the foetus as well, 
the dose of clonidine must be limited to 100 mcg during labour.
Peripheral Nerve Blocks
Clonidine is  commonly used as an adjuvant to local  anaesthetics in peripheral 
nerve blocks where it prolongs the duration of anaesthesia and analgesia. This effect is obtained 
at relatively small doses (75 to 150 mcg) so the risk of side effects. Adding clonidine gives very 
good quality of analgesia after surgery with a duration of over 24 hours for some lower limb 
blocks. However, there is a risk of prolonged motor block, particularly in the elderly patient, 
which could prevent mobilisation.[28]
The quality of intravenous regional anaesthesia produced by lidocaine is improved 
by 150 mcg of clonidine particularly tolerance of the tourniquet. 
Intra-articular analgesia has gained in popularity in recent years, particularly with 
the  greater  number  of  arthroscopies.  performed.  Intra-articular  clonidine  produces  analgesia 
similar to intra-articular morphine.[29]
Thus, clonidine is nowadays used widely as an adjunct to local anaesthetics in 
peripheral  blocks, and its use for intravenous regional anaesthesia or intra-articular analgesia 
appears promising.
Applications in specialized surgery
The effects of the α2-agonists may be particularly useful  for certain types of surgery 
where hypotension or a decrease in intraocular or intracranial pressure is desirable.
Clonidine  causes  direct  vasoconstriction  of  afferent  arteries  of  the  ciliary  process 
resulting in decreased production of aqueous humour,  and also increases outflow of aqueous 
humour by decreasing vasomotor tone of the aqueous drainage system, especially in glaucoma. 
Clonidine has been shown effectively to reduce intraocular pressure and anxiety and to speed 
recovery  in  patients  undergoing  intra-ocular  surgery.  A  single  intravenous  dose  of 
dexmedetomidine  (0.6  μg  kg-1)  reduced  intraocular  pressure  by  34%;  after  intubation  the 
intraocular  pressure was  27%  less  in  the dexmedetomidine-treated group compared with  the 
placebo group. Catecholamine concentrations and blood pressure were also significantly reduced 
in the dexmedetomidine group.
Dexmedetomidine  (1.0  μg  kg-1)  given  intramuscularly  as  premedication  produced 
sedation and a significant reduction in intraocular pressure with minimal haemodynamic side 
effects for day-case cataract surgery performed under regional anaesthesia
Oral  clonidine  premedication  (4-6  μg  kg-1)  reduced  bleeding  and  improved  surgical 
conditions for middle ear surgery.
α2-Adrcnoccptor agonists  may be beneficial  in patients  with intracranial  pathology as 
maintenance of haemodynamic stability and avoidance of hyperdynamic episodes is important. 
The  α2-adrenoceptor  agonists  may  reduce  intracranial  pressure  and  offer protection  during 
cerebral  injury.  They reduce  intracerebral  blood flow;  one  mechanism of  action  may be  by 
reducing requirements for volatile agents and thereby avoiding the vasodilatation induced by 
them.  As  yet,  there  are  no  clinical  studies  on  changes  in  intracranial  pressure  or  cerebral 
protective  effects  of  the  α2 agonists.  Chadha  et  al. reported  that  oral  clonidine  pretreatment 
reduced the haemodynamic responses to surgical stimuli during craniotomy.[3] Although another 
study was less convincing the potential to antagonize the effects of the α2agonists with specific 
α2-antagonists may be useful in neurosurgical anaesthesia where prompt awakening is needed.
Qualifications for inclusion into the neuroanesthesia drug club:
1.Controllability. (e.g. rapid onset and offset of effect)
2.Stability of intracranial homeostasis.
3.Hemodynamic stability.
4.Noninterference with neurophysiologic monitoring.
5.Neuroprotection.
6.Antinonociception.
Anaesthetic sparing 
In animals clonidine reduces MAC by up to 50%, whereas dexmedetomidine reduces 
MAC by more than 90%. Too little is known as yet about the action of dexmedetomidine at high 
doses in humans to make it likely that it will be used as an anaesthetic agent in its own right in 
the near future.  However,  it  has already been shown to have significant  anaesthetic  sparing 
effects in clinical studies.
In patients undergoing abdominal hysterectomy an infusion of dexmedetomidine was not 
quite potent enough to provide anaesthesia without additional isoflurane, but the median expired 
concentration of isoflurane required to maintain haemodynamic variables within predetermined 
limits was decreased by more than 90%, and required for a shorter period of time. 
Ghignone et al’ reported a 45% reduction in fentanyl requirements in patients undergoing 
aortocoronary artery bypass surgery after oral clonidine premedication.[45] In a similar study, 
Flacke and colleagues showed that clonidine premedication reduced sufentanil requirements by 
40%.[12] In contrast, Abi-Jaoude et al  found no opioid sparing effect and no improvement in 
perioperative haemodynamic stability from clonidine premedication.
There may also be pharmacokinetic reasons for the reduction in opioid requirements. In a 
study of patients receiving nitrous oxide, isoflurane and an infusion of alfentanil to maintain 
anaesthesia, premedication with clonidine resulted in a 60% increase in plasma concentration of 
alfentanil compared with patients who had not received clonidine. 
Induction  doses  of  thiopentone  are  reduced  by  pretreatment  with  dexmedetomidine. 
Clonidine  premedication  significantly  decreased  the  requirement  for  propofol-to  maintains 
anaesthesia during surgery.
Haemodynamic effects during general anaesthesia 
Scheinin and colleagues recorded slight decreases in blood pressure and heart rate during 
surgery, a finding reported in other clinical studies performed to date. The increase in systemic 
vascular resistance mediated by postsynaptic α2-adrenoceptors on the peripheral vasculature is 
blunted by the volatile anaesthetic agents especially halothane.
The bradycardia that occurs with dexmedetomidine and clonidine can be marked (less 
than  40  beats/min)  and  is  likely  be  to  exacerbate  when  concomitant  drugs  also  known to 
produce bradycardia are used. Furst and Weinger examined the cardiovascular and respiratory 
effects  of  dexmedetomidine  in  combination  with  alfentanil  in  rats.  Dexmedctomidine  and 
alfentanil given independently reduced heart rate. However, in dexmedetomidine-treated rats the 
addition of alfentanil had no further significant effect on heart rate. Proctor et al compared the 
effects of propofol in dogs, with and without pretreatment with dexmedetomidine (20 μg kg-1). A 
loading  dose  of  propofol  in  the  dexmedetomidine  treated  dogs  increased  heart  rate;  during 
subsequent propofol infusions heart rate returned to control levels.[4]
Treatment  with  anticholinergic  agents  may  attenuate  centrally  mediated  bradycardia 
produced  by  the  α2-adrenoceptor  agonists,  but  the  α2-adrenoceptor  agonists  may  in  turn 
attenuate the response to anticholinergic agents. 
Ventilatory effects during general anaesthesia
Dexmedetomidine (3 μg kg-1) reduced the anaesthetic reguirement (MAC) for isoflurane 
in  dogs  from  1.3%  to  0.37%.  The  ventilatory  depression  caused  by  this  combination  of 
dexmedetomidine and isoflurane was intermediate between the awake state and that during 1.3% 
(MAC) isoflurane anaesthesia. Although the α2-adrenoceptor agonists have synergistic analgesic 
effects  with  the  opioids  they  do  not  appear  to  potentiate  respiratory  depression.  Indeed, 
combination  of  the  two  types  of  drugs  may  reduce  opioid  requirements  and  so  minimize 
ventilatory side effects. Dexmedetomidine reduces the muscle rigidity induced by opioids.[67]
Conclusion 
Alpha2-adrenergic agonists offer a useful and efficient solution to a number of 
anaesthetic problems and can considerably improve management of some patients. These agents 
deserve  to  be  more  widely  used  and  should  be  one  of  the  agent  types  with  which  every 
anaesthetist is familiar.
MATERIAL AND METHODS
40  patients  undergoing  craniotomy  for  excision  of  intracranial  tumors  were 
studied. Patients were selected based on the following inclusion and exclusion criteria:
Inclusion criteria:
1. patients posted for elective craniotomy for intra cranial space occupying lesion excision
2. ASA grade 1 and 2
3. Age 16 to 65yrs.
4. body weight 40 to 80kg
5. haemoglobin not less than 10gms
6. procedures done in supine,prone or lateral position.
Exclusion criteria:
1. brainstem tumor which cause great swings in hemodynamic parameters
2. patients suffering from cvs,rs or renal disease
3. patients with diabetes mellitus with associated autonomic neuropathy
4. patients who are on drugs that affect BP,heart rate or hormonal response
5. BP in preoperative visit >100mmHg
6. obese patients with body mass index more than 29
7. patients with altered consciousness
Sample size and groups:
The sample size was 40 patients suffering from intacranial tumors
Group 1:was a group of 20 patients premedicated with 3.5micrograms/kg of clonidine orally 
90mts prior to induction
Group 2:was a group of 20 patients premedicated with Tab.diazepam 0.2mg/kg body weight 
orally 90mts before induction.
Pre anaesthetic visit:
An overall  assessment  of  the  patient  was  done  as  usual.heart  rate  and  blood 
pressure noted and they were randomly assigned to a group.
Allocation of patients:
Patients were assigned into the two groups by lots taken by a person not taking 
part in the study and they perscribed the premedicationfor the group. The primary investigator 
that is the person doing the study, the surgeon and the anaesthetist of the case were anware of the 
group of the patient. 
Premedication:
1.anticonvulsants and steroids which the patients was on is given to the patient
2.group 1 patients are given clonidine in the dose of 3.5micrograms/kg bodyweight, 90mts prior 
to induction
3.group  2  patients  are  given  diazepam in  the  dose  of  0.2mg/kg  bodyweight  90mts  prior  to 
induction
In the operating theatre the level of sedation is assessed using ramsay sedation 
scale.iv infusions are started using 2 16G iv canula in peripheral veins.Radial artery canlationis 
carried out with 18G iv canula percutaneously either using the transfixationor direct canulation 
technique  after  local  infilteration.The transducer  is  fixed at  the level  of  the externalauditory 
meatus. Baseline heart rate and blood pressure are noted. patient is connected to pulse oximetry 
and the baseline saturationis noted.
Induction intubation sequence:
IV morphine in a dose of 0.1mg/kg bodyweight is given followed by injection 
Thiopentone 2.5% solution is given and the induction dose is calculated usingthe pen grip test in 
which the patient is made to hold a pen in one hand and the dose at which the patient drops the 
pen is noted. This is followed by injection Pancuronium 0.1mg/kg bodyweight intravenously and 
IPPV is inatituted with mask and circle system with 33%oxygen and nitrous oxide.inhalational 
agents Isoflurane is introduced at this stage depending on the heart rate and blood pressure.iv 
2%lignocaine  1.5mg/kg  is  given  intravenously  90secs  prior  to  intubation  and  injection 
Thiopentone2.5% is given in a dose of 1mg/kg bodyweight 60secs prior to laryngoscopy and 
heart rate, systolic, diastolic blood pressure and mean arterial blood pressure are noted before 
and  after  laryngoscopy.  Heart  rate,  systolic  and  diastolic  blood  pressure  and  mean  arterial 
pressure are noted before and after every event namely intubation, infiltration with adrenaline, 
incision, raising the bone flap and extubation and the values are maintained at baseline level to 
30%below baseline using other supplemental drugs like metoprolol and propofol infusion and 
inhalational agents and these drugs are scored using the scoring system shown in the appendix. A 
urinary catheter is inserted.
Maintenance of anesthesia:
IPPV is instituted with 33%xygen and nitrous oxide to maintain ETCO2 between 
25  and  30mmHg.Isoflurane  isused  to  maitainheart  rate  and  blood  pressure.Top  up  doses  of 
pancuronium bromide  are  given  usng a  second twitch  to  TOF stimuli  in  a  peripheral  nerve 
stimulator.At  all  steps during thesrgery theheart  rateand bloodpressure are  maintained in  the 
range of baseline to 30%below it using the supplemental drugs and inhalational agents.
Monitoring:
The patient is connected to the following monitors:
ECG
Intra arterial blood pressure
ETCO2
U/O
Blood loss
Neuromuscular monitoring
Pulse oximeter
Fluid therapy:
0.9%NS is given intravenously 2ml/kg bodyweight and then upto 50% of urine 
output  is  replaced  with  NS.Blood  loss  of  lessthan  10%  iseither  replaced  with  colloid  or 
crystalloid solutions and a loss morethan 10% is replaced with wholeblood.
Emergence:
Neuromuscular  blockadeis  reversed  with  glycopyrolate  and  neostigmine 
40micrograms/kg  bodyweight.Patient  is  extubated  and  supplemental  oxygen  is  given  and 
patientis shifted to the neuro intensive care unit.The level of sedation is assessed.
Results
The results were interpreted with the ‘t’ test and the ‘p’ value for mean of independent samples 
were calculated with a confidence interval of 95%.
Table – I shows the sex distribution between the to groups.
Table – II shows the age, weight and duration of anaesthesia between the two groups. There is no 
significant difference between the two groups.
Table  –  III  shows  the  sedation  scores  pre-operatively  and  postoperatively  between  the  two 
groups. All the patients [ except one in group II ] had pre-op and post-op sedation score of 2. 
there was no significant difference in the sedation score of the two groups.
Table – IV shows the mean HR, SBP, DBP and MAP after each event such as premedication, 
induction, intubation, infiltration, incision, bone flap and extubation.
1. There was no significant difference in the variables pre-operatively.
2. After premedication there was a significant reduction in SBP, DBP and MAP in the 
clonidine group compared to diazepam group. There is no significant change in heart 
rate.
3. After  induction there is  a significant difference in the difference in SBP, DBP & 
MAP between the two groups. There is no significant difference in heart rate.
4. After intubation there is a significant difference only in the heart rate between the two 
groups. The difference in SBP, DBP & MAP  are not significant.
5. After  infiltration  there  is  no  significant  difference  in  heart  rate  between  the  two 
groups, but there is  significant difference in SBP, DBP & MAP between the two 
groups.
6. After incision there is a significant difference in HR, SBP, DBP & MAP between the 
two groups.
7. After  bone  flap  there  is  a  significant  difference  in  SBP,  DBP  &  MAP  but  no 
significant difference in heart rate between the two groups.
8. After extubation there is no significant difference in HR, SBP, DBP & MAP between 
the two groups.
Table – V shows the mean of difference in HR, SBP, DBP &MAP before and after various 
events in surgery like premedication, induction, intubation, infiltration, incision, bone flap and 
extubation
1. The  difference  in  HR,  SBP,  DBP  &  MAP  before  and  after  premedication  had  a 
significant difference between the two groups.
2. There was no significant difference in HR, SBP, DBP & MAP  before and after induction 
in the two groups.
3. There was a significant difference between the two groups in the variation in DBP & 
MAP before and after intubation but no significant difference in variation in HR & SBP.
4. There was a significant difference between the two groups in the variation in HR, SBP & 
MAP before and after infiltration but the variation in DBP was not significant.
5. There was a significant difference between the two groups in the variation in HR, SBP, 
DBP & MAP before and after incision.
6. There was no significant difference between the two groups in the variation in HR, SBP, 
DBP & MAP before and after bone flap.
7. There was a significant difference between the two groups in the variation in HR, SBP & 
MAP but not DBP before and after extubation.
Table – VI shows the number of patients with the different scores for each agent in the two 
groups. The score was significantly higher in group II. 

DISCUSSION
Premedication is  not  only for  sedation and anxiolysis  but  also to  enhance the 
quality of induction, maintenance and recovery from anaesthesia.
Primary concern of a neuroanaesthetist in tumor surgery is to avoid fluctuations in 
blood pressure, coughing and straining. Patients with intracranial tumor are at steep part 
of intracranial compliance curve so, even small increases in cerebral blood volume cause 
marked increase in intracranial pressure. Over a wide range changes in cerebral blood 
flow is directly proportional to PaCO2. Changes in PaO2 have little influence on cerebral 
blood flow in the auto regulatory pressure range of 60-130 mm hg. If PaO2 falls below 60 
CBF increases markedly.
Induction and intubation is the most challenging part of neuroanesthesia. Main 
aim  of  neuroanesthetist  is  to  obtund  the  pressor  response  and  tachycardia  during 
intubation. Moreover hypertension has to be prevented even during other events such as 
infiltration, incision and raising the bone flap. Rise in systolic blood pressure increases 
the cerebral blood volume there by increasing the intracranial pressure, which in turn 
leads to decreased cerebral perfusion pressure. Therefore hypertension causes secondary 
brainstem injury through herniation and ischaemia. Ischaemia in turn leads to enlarging 
areas  of  tissue  acidosis,  which  causes  cerebral  vasomotor  paralysis.  This  causes  the 
cerebral blood flow to become pressure passive.
Herniation occurs at the following sites:
1. Uncal.
2. Transtentorial.
3. Transcalvarial
4. Subfalcine
5. Tonsillar
Uncal  herniation causes oculomotor  palsy leading on to ptosis,  mydriasis,  and 
hemianopia due to  posterior  cerebral  artery compression,  hemiparesis  due to  cerebral 
peduncle  compression.  Central  tentorial  herniation  causes  decerebrate  rigidity  due  to 
involvement of corticospinal tract.  Midbrain and pontine compression causes irregular 
respiration. Medullary tonsillar herniation causes hypertension bradycardia and apnea.
Volatile  anesthetics  impair  autoregulation.  They increase  cerebral  blood  flow, 
cerebral blood volume thereby raising ICP. They decrease the cerebral metabolic rate and 
increase the cerebral blood flow thereby causing an uncoupling of flow and metabolism.
Thiopentone  decreases  CMRO2 and  cerebral  blood  flow  thereby  decreasing 
cerebral  neuronal  function.  It  is  a cerebral  vasoconstrictor.  It  also attenuates  the CO2 
response.
Beta-blockers are used to attenuate the stress response during intubation. They are 
contraindicated  in  asthmatics.  There  are  accounts  of  cardiac  arrest  in  patients  with 
subarachnoid hemorrhage.
IV lidocaine obtunds laryngosympathetic reflexes, decreases cerebral blood flow 
and depresses the SA node.
Propofol causes decrease in  CMRO2,  reduces MAP, but increases the cerebral 
blood volume.  At low doses it is neuroexitatory whereas at high doses it depresses the 
neuronal function.
Clonidine is an antihypertensive agent used to produce hemodynamic stability during 
intubation and during the course of surgery. In order to protect the control group (i.e. 
patients given diazepam) supplemental drugs were used such as beta-blockers, 
propofol and isoflurane. A scoring system was used to measure the usage of these 
drugs, which is shown in the appendix. Clonidine also has the unique advantage of 
producing sedation without causing respiratory depression. It also potentiates 
morphine-induced analgesia.
As  per  the  study  the  two  groups  were  similar  in  the  age,  sex  and  weight 
distribution. The duration of surgery in both the groups ranged from 3 – 4 hours. Patients 
belonging to both the groups had similar preoperative heart rate and blood pressure.
There was no difference in the preoperative and postoperative sedation scores. All 
the  patients  have  a  sedation  score  of  2,  except  one  patient  in  group  I  who  had 
preoperative sedation score of 1. 
There  was a  significant  reduction  in  the  induction  dose  of  thiopentone  in  the 
clonidine  group.  The  dose  of  thiopentone  was  14%  less  in  the  clonidine  group  as 
compared with the diazepam group.
The HR & BP after premedication was significantly lower in the clonidine group. 
There was a 10 % reduction in heart rate and 8% reduction in MAP in the clonidine 
group as compared to the 3% reduction in the heart rate and 2% decrease in MAP in the 
diazepam group.
There was no significant difference in the HR & BP in the two groups during 
induction and intubation.
During each event in surgery there was a significantly lower HR & BP in the 
clonidine group (for e.g. there was a 7% difference in the MAP of the two groups after 
infiltration, 9% after incision and 10% after bone flap). The heart rate in the clonidine 
group was 8% less than the diazepam group after incision.
When we compare the change in HR & BP during each event in surgery in the 
two groups there was a better haemodynamic stability in the clonidine group (for e.g. 
there was a 50% greater change in HR in the diazepam group after infiltration, 60% after 
incision and 80% more variation after extubation. There was a 50% greater variation in 
MAP after incision in the diazepam group in comparison with the clonidine group and 
90% after infiltration and after extubation).
The blood loss was also lower in the clonidine group but the surgeon’s assessment 
of the field of surgery was not significantly different in the two groups.
There was a 40% reduction in the total score of the clonidine group. The number of 
patients with higher isoflurane scores was significantly lesser in the clonidine group. 
60% had a score of 1. 3% had a score of 2 and none had a score of 3 in the clonidine 
group. As compared to this, 20% had a score of 1, 75% had a score of 2 and 5% gad a 
score of 3 in the diazepam group. The usage of propofol infusion was also 
significantly lower in the clonidine group. 15% had a score of 1, and 5% had a score 
of 2 and none had a score of 3 in the clonidine group. Whereas in the diazepam group 
20% had a sore of 1, 20% had a score of 2 and 5% had a score of 3. the use of 
metoprolol was also less in the clonidine group. 5% had a score of 2 in the clonidine 
group whereas 5% had a score of 1 and 10% had a score of 2 in the diazepam group.
It is evident from the presented data that the use of supplemental drugs was 
significantly lower in the clonidine group.
The above data clearly indicates that clonidine offers much greater haemodynamic 
stability during craniotomy.
Summary
This double blind prospective randomized control study was designed to 
evaluate  the  efficacy,  usefulness  and  safety  of  oral  clonidine  premedication  in 
neurosurgical patients posted for elective intracranial tumor excision. Oral diazepam in a 
dose of 0.2 mg/kg served as control. 
A total of 40 patients belonging to ASA physical status I & II, belonging 
to  the  age  group  between  16  &  65  years  and  posted  for  elective  intracranial  tumor 
excision were divided into two groups. 10 males and 10 females in group I received oral 
clonidine in a dose of 3.5 µg/kg orally 90 minutes prior to induction. 12 males and 8 
females in group II received 0.2 mg/kg  diazepam prior to induction. The HR, SBP, DBP 
& MAP were noted during the preoperative visit after premedication  and various events 
such as induction, intubation, infiltration, incision, bone flap and extubation. The use of 
various supplemental agents such as isoflurane, propofol and Metoprolol were also noted. 
The following observations were noted:
1. The induction dose of thiopentone was lower in the clonidine group.
2. The HR& BP after premedication were lower in the clonidine group.
3. The  HR  &  BP  during  various  events  stated  above  were  lower  in  the 
clonidine group except during induction and intubation.
4. The variations in the HR & BP were also less in the clonidine group.
5. Blood loss was lower in the clonidine group.
6. the use of supplemental agents as stated above was also lower in the clonidine 
group.
Conclusion
We conclude that by using clonidine to manipulate the central MAO pathways involved 
in sympathetic responses to noxious stimuli can decrease the peaks and valleys ( Alpine 
anaesthesia  )  and smoothen out  anesthesia  in  craniotomy.  A dose of  3.5 µg/kg body 
weight of clonidine orally 90 minutes prior to induction safely and effectively blocks the 
pressor  and  HR  response.  It  also  decreases  the  requirement  of  other  supplemental 
anaesthetic  agents.  Clonidine  causes  dose  related  sedation,  anxiolysis,  reduction  of 
secretions, peri operative hemodynamic stability, analgesia, reduction in requirements of 
anaesthetic  agents.  Clonidine  is  beneficial  in  neurosurgical  patients  with  intracranial 
tumors  for  maintenance  of  hemodynamic  stability  and  avoidance  of  hyperdynamic 
episodes, reduction in intracranial pressure and offers protection during cerebral injury. 
Due to various properties such as controllability, stability of intracranial homeostasis, non 
interference  with  neurophysiologic  monitoring  clonidine  can  be  safely  used  as  a 
premedicant in neuroanaesthesia.  
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